Pre-market most active BAYN.DE Bayer (XETRA) €45.80 07 Feb 2026: earnings steer trend

BAYN.DE stock is trading at €45.80 in pre-market on 07 Feb 2026, up 2.20% as volume runs above average. Investors are pricing in a mix of crop science strength and upcoming Pharmaceuticals updates ahead of a late-February earnings release. Trading volume is sizeable at 4,241,468.00 shares, marking BAYN.DE as one of today’s most active XETRA names. We examine valuation, technicals, and the Meyka AI forecast that frames near-term price expectations.

BAYN.DE stock: pre-market price, range and volume

BAYN.DE stock opened at €45.90 and sits at €45.80 in pre-market, above yesterday’s close of €44.82. The intraday range so far is €44.64 to €46.25, and trading volume is 4,241,468.00 versus average volume 3,435,837.00. Elevated volume with a positive change of €0.98 suggests active repositioning ahead of the earnings date on 25 Feb 2026.

BAYN.DE stock: valuation and fundamentals

Bayer AG (BAYN.DE) shows a price-to-sales ratio of 0.98 and a price-to-book ratio of 1.52, indicating the market values sales and equity conservatively. Trailing EPS is -0.20 with a PE of -229.00, reflecting recent headline-related adjustments to net income. Free cash flow yield is 8.75%, and debt-to-equity stands at 1.34, which flags leverage as a material risk versus peers in Healthcare.

BAYN.DE stock: technicals and momentum

Technically, BAYN.DE stock sits with an RSI of 73.81, signaling short-term overbought conditions. The 50-day average is €38.83 and the 200-day average is €29.96, both below current price and supporting a bullish medium-term trend. On-balance volume and ADX (46.38) show strong trend participation, but overbought indicators warrant caution for new entrants.

BAYN.DE stock: sector context and peers

Bayer trades in the Healthcare sector on XETRA and faces mixed sector performance, where healthcare has outperformed some sectors by ~1.15% YTD. Crop Science strength contrasts with pressure in Pharma margins industry-wide. Relative to drug manufacturers, Bayer’s return on equity of -0.64% lags peers, while gross margin at 56.35% remains competitive.

BAYN.DE stock: risks, catalysts and earnings pathway

Key risks for BAYN.DE stock include litigation exposures, integration costs in Crop Science, and leverage with netDebt/EBITDA near 5.53x. Catalysts include the earnings release on 25 Feb 2026 and potential pipeline readouts in oncology. Short-term momentum could hinge on management guidance and margin commentary at the report.

BAYN.DE stock: Meyka AI grade and model view

Meyka AI rates BAYN.DE with a score of 68.06 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 3-month target of €51.73 and a monthly target of €47.50; these reflect trend continuation but carry model caveats and are not guarantees.

Final Thoughts

BAYN.DE stock trades at €45.80 pre-market on 07 Feb 2026 with above-average volume, making it one of XETRA’s most active names today. Valuation metrics show attractive price-to-sales at 0.98 and a reasonable price-to-book at 1.52, yet negative EPS and elevated leverage add risk. Technically, the stock is overbought with RSI 73.81, but moving averages point to a stronger medium-term trend. Meyka AI’s forecast model projects a 3-month target of €51.73, implying an upside of 12.95% from the current price. Forecasts are model-based projections and not guarantees. For active traders, the upcoming earnings on 25 Feb 2026 is the main catalyst; for longer-term investors, monitor free cash flow yield 8.75% and net-debt metrics before increasing exposure. Use our Meyka BAYN.DE page for live updates and note that external coverage tracks developments (MarketBeat, Investing.com). Meyka AI is an AI-powered market analysis platform; our grade and forecast inform analysis, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.